OXIS International, Inc. Announces the Appointment of Dr. John Repine to Its Scientific Advisory Board

News provided by

Aug 09, 2010, 09:25 ET

BEVERLY HILLS, Calif., Aug. 9 /PRNewswire-FirstCall/ -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) is extremely proud to announce the appointment of Dr. John Repine to the OXIS International Scientific Advisory Board. Dr. John Repine is the James J. Waring Professor of Medicine, Pediatrics and Surgery and the Director of the Webb-Waring Center for Oxidative Stress Research at the University of Denver Colorado Health Sciences Center.

Dr. Repine has guided the Webb-Waring Institute since 1993. Under his leadership the Institute's research program has shifted its focus to a multi-disciplinary study and teaching of inflammation and antioxidant biomedical research. This strategy brings together M.D. and Ph.D. trained scientists and physician scientists in an interactive approach focused on the cause and prevention of aging and many common diseases including cancer. The work of Dr. Repine and his team is consistently well supported by Foundations and National Institutes of Health (NIH) grants. For example, Dr. Repine has been the Principal Investigator on more than $13 million in NIH grants including being the head for 10 years of one of five national NIH sponsored Specialized Centers of Research (SCOR) for Acute Lung Injury (a.k.a. the Acute Respiratory Distress Syndrome, ARDS)

Dr Repine is the author of more than 300 original peer-reviewed research articles, review articles and book chapters. A respected authority in the study of vascular diseases including ARDS, diabetes and ischemia-reperfusion disorders (heart attack and stroke), he has lectured at more than 200 national and international meetings and symposia and is a widely recognized expert concerning antioxidants and inflammation.

Dr. Repine is a member of many professional and honorary societies for medicine, chemistry and biology. He was elected to the American Society of Clinical Investigation, Association of American Physicians and as a counselor to the Oxygen Society. He is the recipient of an Established Investigator Award from the American Heart Association, Basil O'Conner Research Award from the March of Dimes, the Bonfils-Stanton Award for his Outstanding Contributions to Medicine and Science and the National Alton Ochsner Award Relating Smoking and Health. In addition, Dr. Repine was recently chosen to receive the coveted Senior Scholar in Aging Award following a two-stage national competition by the Ellison Medical Foundation.

Working closely with industry, Dr. Repine serves as a founder, board member and on the scientific advisory boards of a number of biotechnology companies and is currently developing, testing and patenting promising products for the detection, monitoring, treatment and prevention of disease in his role with OXIS International. He is the inventor on 14 patent applications. Dr. Repine has also been a leader and member of many local and national committees including the Medical Student Research Program, the University of Colorado Technology Transfer Program and the International Task Force regarding the role of Oxidants in Emphysema and Lung Cancer and an NIH/DOD panel on the pulmonary challenges of bio-terrorism. Dr. Repine is a Trustee of the Bonfils-Stanton Foundation, the Kent Denver School and a member of Alpha Omega Alpha.

Dr. Repine graduated from the University of Wisconsin in 1967 and obtained his M.D. in 1971 from the University Of Minnesota School Of Medicine where he won the Borden Prize for outstanding research and was chosen in 2006 for the Distinguished Alumni Award for Outstanding Contributions to Medicine. Dr. Repine completed advanced clinical training in internal medicine and a fellowship in pulmonary/critical care medicine at the University of Minnesota.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.

Forward-Looking Statement

This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.

www.oxis.com

SOURCE OXIS International, Inc.